Business Wire

Announcing Marketing Approval for Hunterase ICV Injection 15 mg, the World’s First Enzyme Replacement Therapy for Mucopolysaccharidosis Type II (Hunter Syndrome) Administered ...

YONGIN, South Korea--(BUSINESS WIRE)--GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, and Clinigen K.K. (“Clinigen”), headquartered in ...
PR Newswire

National Center for Child Health and Development Initiates Phase 1/2 Trial of Green Cross' idursulfase-beta ICV for the Treatment of Hunter Syndrome with Neurocognitive Decline

YONGIN, South Korea, Oct. 26, 2016 /PRNewswire/ -- Green Cross Corporation (Green Cross) (KRX: 006280), a South Korean biopharmaceutical company, and the National Center for Child Health and ...